Latest News and Press Releases

BASEL, Switzerland, June 23, 2003 (PRIMEZONE) -- Novartis (Other OTC:NVSEF) today announced new study data found that liver transplant patients receiving Neoral (cyclosporin for microemulsion) and...

BASEL, Switzerland, June 20, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS)(Other OTC:NVSEF): Data from key clinical Phase III studies presented for the first time at EULAR, the European League Against...

BASEL, Switzerland, May 20, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS)(Other OTC:NVSEF): New data from a large pivotal US trial demonstrates Zelmac(R) (tegaserod) was significantly more effective...

BASEL, Switzerland, May 9, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) (Other OTC:NVSEF): Incontinence treatment Enablex(R) purchased from Pfizer for up to USD 225 million 51% of Idenix acquired,...

BASEL, SWITZERLAND, Switzerland, April 24, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) (Other OTC:NVSEF): launches international education program to ensure effective treatment with its fixed dose...

BASEL, Switzerland, April 15, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) (Other OTC:NVSEF): -- Group sales up 21% in USD (13% in local currencies); Pharmaceuticals grows by 18% in USD (10% in...

Basel, Switzerland, April 14, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) (Other OTC:NVSEF): Please note that we will publish our Group financial results for the first quarter of 2003 on Tuesday, April...

BASEL, Switzerland, April 9, 2003 (PRIMEZONE) -- The Novartis Group (NYSE:NVS) (Other OTC:NVSEF) has won an important ruling in its legal dispute with GlaxoSmithKline (GSK) concerning AmoxC...

BASEL, Switzerland, March 28, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) (Other OTC:NVSEF): - Partnership with Regeneron for IL-1 Cytokine Trap compound in phase II clinical development. - Agreement...

BASEL, Switzerland, March 18, 2003 (PRIMEZONE) -- Novartis announced today that it will further strengthen its primary care product portfolio through the acquisition of Pfizer's M3 antagonist,...